Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Celularity Inc (CELUW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: CELUW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.76 | 52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.77% | Operating Margin (TTM) -52.25% |
Management Effectiveness
Return on Assets (TTM) -17.42% | Return on Equity (TTM) -232.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11684589 |
Shares Outstanding - | Shares Floating 11684589 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was founded in 2016, emerging from Celgene's (now Bristol Myers Squibb) cell therapy assets. It focuses on cellular medicines and biomaterials derived from the postpartum human placenta. It went public via SPAC in 2021.
Core Business Areas
- Cellular Medicines: Development of allogeneic, off-the-shelf cell therapies for cancer, infectious diseases, and degenerative diseases.
- Biomaterials: Development and commercialization of biomaterials for wound care, orthopedic and surgical applications derived from placental tissues.
Leadership and Structure
Robert J. Hariri, M.D., Ph.D., is the Founder, Chairman and Chief Executive Officer. The company has a standard corporate structure with a board of directors and executive management team overseeing research and development, clinical trials, commercialization, and finance.
Top Products and Market Share
Key Offerings
- CYNK-001: An allogeneic natural killer (NK) cell therapy in clinical development for hematologic malignancies and solid tumors. Market share data is not publicly available. Competitors include Fate Therapeutics, NantKwest (now ImmunityBio), and other companies developing NK cell therapies.
- PDA-002: Placental-derived biomaterial product used in wound care applications. Market share data is not publicly available. Competitors include Organogenesis, MiMedx, and other companies in the advanced wound care market.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in regenerative medicine and immunotherapy. The biomaterials market is also experiencing growth due to the increasing demand for advanced wound care and surgical solutions.
Positioning
Celularity is positioned as a leader in placental-derived cell therapies and biomaterials. Its competitive advantage lies in its access to postpartum placental tissue and its proprietary platform technologies.
Total Addressable Market (TAM)
The total addressable market for cell therapies and biomaterials is estimated to be in the tens of billions of dollars. Celularity is focused on capturing a significant share of this market through its innovative products and clinical development programs.
Upturn SWOT Analysis
Strengths
- Proprietary placental-derived cell therapy and biomaterial platform
- Experienced leadership team
- Strong intellectual property portfolio
- Clinical-stage pipeline of cell therapy candidates
Weaknesses
- Relatively small revenue base
- Dependence on clinical trial success
- High cash burn rate
- Limited commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
- Increasing adoption of cell therapies and biomaterials
Threats
- Competition from other cell therapy companies
- Regulatory hurdles
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BMY
- NK
- CRSP
- EDIT
- BLUE
Competitive Landscape
Celularity faces intense competition in the cell therapy and biomaterials markets. It needs to differentiate itself through its unique placental-derived technology and clinical success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research and development advancements and strategic partnerships. Revenue growth has been variable.
Future Projections: Future growth is dependent on the successful completion of clinical trials and commercialization of its cell therapy candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing its clinical pipeline, expanding its biomaterials product line, and pursuing strategic collaborations.
Summary
Celularity Inc. is a clinical-stage biotechnology company with a focus on placental-derived cell therapies and biomaterials. The company has a strong intellectual property portfolio and experienced leadership, but faces challenges related to clinical trial success, regulatory hurdles, and competition. Its future growth depends on successfully commercializing its products and expanding its partnerships. The lack of revenue and potential cash burn rate need to be considered.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Celularity Inc. SEC filings
- Company website
- Third-party research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-07-19 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.celularity.com |
Full time employees 123 | Website https://www.celularity.com | ||
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.